Anbio Biotechnology Cash Flow Statement (2024-2025) | NNNN

Cash Flow Statement Dec2024 Jun2025
Operating Activities
Change in Working Capital
Change in Account Payables 1,625.26B60.35B
Change in Accured Expenses 104.98B70.78B
Other Working Capital Changes 5,683.09B10,173.06B
Financing Activities
Other financing activities 387.44B6,563.63B